michael r. mowatt, ph.d. director, technology transfer and intellectual property office
TRANSCRIPT
Partnering with the National Institute of Allergy and Infectious Diseases
Michael R. Mowatt, Ph.D.
Director, Technology Transfer and Intellectual Property Office
2
On Tap Today
• Our mission, our organization• Resources to advance development and
commercialization• TTIPO: Your partnering partner• Discovery, Innovation, Invention, and
Intellectual Property• Changes coming to NIH• What’s on your mind?
3
Mission
To support and conduct basic research to better understand, treat, and prevent infectious, immunologic and allergic diseases
Department of Health and Human
Services (HHS)National Institutes
of Health (NIH)
National Institute of Allergy and
Infectious Diseases (NIAID)
4
Budget
Second largest among Institutes and Centers at NIH – 15% of total NIH appropriation
$4.4 billion in Fiscal Year 2014
5
Structure
Office of the
Director
Extramural Research
80% of the budget
Intramural Research
10% of the budget
6
Organization: Extramural Research
Office of the Director
Division of AIDS (DAIDS)
Division of Allergy,
Immunology and Transplantation
(DAIT)
Division of Microbiology and
Infectious Diseases
(DMID)
7
Need Funding?
http://www.niaid.nih.gov/researchfunding/pages/default.aspx?wt.ac=tnFunding
8
Looking for Resources?
http://www.niaid.nih.gov/LabsAndResources/resources/Pages/default.aspx
9
Need Help with Clinical Trials?
http://www.niaid.nih.gov/about/organization/daids/research/Pages/default.aspx
10
Organization: Intramural Research
Office of the DirectorDivision
of Clinical Research
(DCR)
Division of
Intramural
Research (DIR)
Vaccine Research
Center (VRC)
11
Intramural Resources
Know-how NIAID-developed technologies Research tools and materials Animal models Biocontainment facilities Experience in collaborating with foreign entities and
sponsoring international clinical trails
12
Finding What You Need: NIH RePORTER
• Covers NIH funded research
• Potential collaborator search
• Keyword search • PI search • Funding mechanism
search
13
Interested in Collaboration?
TTIPO WILL HELP YOU TO
• Match your interests with NIAID interests and resources• Direct you to the right person • Facilitate communication with NIAID• Develop a collaboration plan• Help navigate NIAID resources • Put necessary agreements in place
http://www.niaid.nih.gov/LabsAndResources/techDev/Pages/about.aspx
14
TTIPO:We Speak Your Language
J.D., M.B.A., M.S., and Ph.D. Patent agents and attorneys Former patent examiners (USPTO) Research and R&D experience in industry, academia,
government Business development and technology licensing
experience Paralegal and administrative experience
Technology Transfer and the Research Cycle
Transfer InRESEARCH
KNOWLEDGEIDEAS
PUBLICATION INVENTION
DEVELOPMENT
COMMERCIALIZATION Transfer Out
16
Discovery Invention
Development and
Commercialization
Materials
MTACRADA
RCA
Information
CDACRADA
RCA
$$$
CRADAGrantGift
Partner
$$$
CRADAGrantGift
Technology Transfer:Discovery to Marketplace
PubAgrmt
Publication
EIR
PatentLicense
Public Investment Public Benefit
NIAID TT: Worldwide Impact
TT Success Stories Ebola Vaccine“…the National Institute of Allergy and Infectious Diseases reported that an experimental vaccine it developed, along with the pharmaceutical giant GlaxoSmithKline, had produced good results in tests with 20 healthy adults, who developed antibodies against Ebola” Mark Landler/The New York Times
FluMistDecades of NIAID-funded research helped create FluMist, the first nasal spray vaccine for influenza approved by the Food and Drug Administration.
TT Success Stories
Developing the World’s First Licensed Hepatitis A Vaccine
NIAID scientists played a crucial role in the development of Havrix, the world’s first licensed hepatitis A vaccine. Developing Novel Tuberculosis DrugsA drug-resistant tuberculosis drug candidate SQ109, uncovered by NIAID scientists, is under further development by a Rockville-based Sequella, Inc.
SYNAGIS (palivizumab):A case study
# 47 Top Pharmaceutical Product by Global Sales ($1.9B in 2013) The only preventive therapy for children at risk for RSV
A brief history• NIAID pediatrician Robert M. Chanock and his team showed
that anti-RSV antibodies protected cotton rats from RSV infection (early 1980s)
• NIAID scientists developed monoclonal antibodies that efficiently neutralized RSV infection
• MedImmune modified one of the NIAID antibodies by splicing it to a human protein. This created a “humanized” antibody that prevented RSV in humans
• Synagis (palivizumab) was approved by the FDA in 1998
Recently in the News
FOR IMMEDIATE RELEASEWednesday, Oct. 15, 2014
NIH Grants License Agreement for Candidate Ebola Vaccines
Ebola Vaccines Based on Established Rabies Vaccines May Protect Against Both Diseases
The vaccines were created by scientists at NIAID and Thomas Jefferson University (TJU) in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
http://www.niaid.nih.gov/news/newsreleases/2014/Pages/EbolaVaxLicense.aspx
22
22
SBIR/STTR Program
NIAID funds ~ $118 million in Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards using set-aside funds mandated by Congress
23
DAIDS DAIT DMID0
100
200
300
400
500
600
65131
523
14 1544
Application Submit-tedApplication Funded
DAIDS, DAIT, DMIDSBIR/STTR Grants FY 2013
Division of AIDS (DAIDS)Division of Allergy, Immunology and Transplantation (DAIT)Division of Microbiology and Infectious Diseases (DMID)
SBIR/STTR FY 2013-14
CA MD MA PA NY WA CO OR CT TX
0
10
20
30
40
50
60
70
80
9081
3733
2523
16
11 1110 10
Number of Grants
Number of Grants
Total Number of Grants: 335
Total Number of Maryland Grants: 37
Total Number of Grants to Montgomery County Businesses: 27
NIAID SBIR - Technology Transfer Direct Phase II (SBIR-TT)
An opportunity for a small business to develop NIAID-originating invention
First Funding Opportunity was limited to Diagnostics and closed in November; Applications are currently under evaluation
Next Funding Opportunity will be directed towards vaccines
We need your help with spreading a word: what’s the best way to reach small businesses?
Partnership Opportunity: Hepatitis C (SBIR-TT) Cloned genomes of infectious hepatitis C viruses and uses
thereof
Opportunity for a small business to collaborate on NIAID’s technology that provides nucleic acid sequences which comprise the sequences of genotype 1a and 1b strains of infectious hepatitis C viruses. The technology relates to the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of diagnostic assays for HCV and screening assays for the identification of antiviral agents for HCV.
http://www.niaid.nih.gov/researchfunding/sb/Pages/sbir-ttlist.aspx#3
Partnership Opportunity: Ebola
Dr. Nancy Sullivan is looking for partners to develop a kit based on her novel non-invasive method for Ebola virus detection in great apes and other wildlife hosts.
Please contact TTIPO for more information
President Obama and Nancy J. Sullivan at the Vaccine Research Center in Maryland on Tuesday. Credit Doug Mills/The New York Times
http://www.niaid.nih.gov/LabsAndResources/techDev/Pages/about.aspx
28
Discovery Invention
Development and
Commercialization
Materials
MTACRADA
RCA
Information
CDACRADA
RCA
$$$
CRADAGrantGift
Partner
$$$
CRADAGrantGift
Changes Coming to NIH Technology Transfer
PubAgrmt
Publication
EIR
PatentLicense
Public Investment Public Benefit
29
What’s on your mind?
Thank you for your attention!